Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 07, 2021

SELL
$15.31 - $26.52 $205,337 - $355,686
-13,412 Closed
0 $0
Q4 2020

Mar 02, 2021

BUY
$16.84 - $27.59 $225,858 - $370,037
13,412 New
13,412 $357,000
Q4 2020

Feb 10, 2021

SELL
$16.84 - $27.59 $225,858 - $370,037
-13,412 Closed
0 $0
Q3 2020

Nov 12, 2021

BUY
$16.2 - $25.7 $217,274 - $344,688
13,412 New
13,412 $250,000
Q2 2018

Jul 23, 2018

SELL
$14.2 - $22.68 $284,000 - $453,600
-20,000 Closed
0 $0
Q1 2018

May 15, 2019

BUY
$13.56 - $18.48 $271,200 - $369,600
20,000 New
20,000 $315,000
Q1 2018

May 09, 2018

SELL
$13.56 - $18.48 $271,200 - $369,600
-20,000 Closed
0 $0
Q4 2017

Mar 05, 2018

BUY
$14.95 - $19.9 $299,000 - $398,000
20,000 New
20,000 $329,000
Q4 2017

Feb 09, 2018

SELL
$14.95 - $19.9 $299,000 - $398,000
-20,000 Closed
0 $0
Q3 2017

Nov 13, 2018

BUY
$14.8 - $18.06 $296,000 - $361,200
20,000 New
20,000 $346,000
Q3 2017

Nov 07, 2017

SELL
$14.8 - $18.06 $296,000 - $361,200
-20,000 Closed
0 $0
Q2 2017

Jul 24, 2018

BUY
N/A
20,000
20,000 $279,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $44.7M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.